Investigational DAA treatment combination effective and improves patient-reported outcomes

(European Association for the Study of the Liver) Analysis of patient outcome data from the POLARIS-1, 2, 3 and 4 studies demonstrate that patients with HCV and cirrhosis have greatest improvements of PRO scores when taking treatment with sofosbuvir + velpatasvir, ± voxilaprevir, an anti-HCV regimen that has been shown to be safe and effective against all HCV genotypes. The analysis, presented at The International Liver Congress ™ 2017 in Amsterdam, The Netherlands, showed that achievement of SVR12 was associated with improvements in PROs.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news